1、1 On the Cusp of a CureIs Asia Pacific Ready for the Precision Era?China1 L.E.K.Consulting|On the Cusp of a CureOn the Cusp of a CureIs Asia Pacific Ready for the Precision Era?L.E.K.Consulting is a registered trademark of L.E.K.Consulting LLC.All other products and brands mentioned in this document
2、 are properties of their respective owners.2025 L.E.K.Consulting LLC32 L.E.K.Consulting|On the Cusp of a CureL.E.K.Consulting|On the Cusp of a CureAcknowledgements L.E.K.Consulting would like to acknowledge the contributions of all the Advisory Committee members who have provided critical insights i
3、nto the development of this report.Specifically,their contributions have guided the assessment of barriers facing the adoption of precision therapies investigated and recommendations to addressing these barriers.NamePositionOrganisation AustraliaDavid ThomasChief Scientific OfficerOmicoJaala Pulford
4、Chair of the BoardMTPConnectChristine CockburnCEORare Cancers AustraliaChinaBaorong YuProfessor and market access key opinion leaderUniversity of International Business and EconomicsAndy MokHead of ChinaGuardant HealthKevin HuangFounder and presidentChina Organization for Rare Disorders(CORD)Caicun
5、ZhouProfessor and lung cancer key opinion leaderSchool of Medicine,Tongji UniversityJapanTeruyuki KatoriRepresentative Director Specially Appointed ProfessorFuture Institute Wolong,General Incorporated Association Graduate School of Social Sciences,University of HyogoDaisuke SatoProfessorFujita Heal
6、th universityManabu MutoProfessorKyoto University Graduate School of MedicineMasahiro MiyakeProfessorKyoto University HospitalNaomi SakuraiFounder and CEOCancer Solutions Keisuke ShimizuLeader Lung cancer HER2 HER HERSouth KoreaPaul LeeFormer GMGilead Sciences KoreaJin-Ah KimAdvocate for rare diseas